World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
61591
World Ranking
9066
National Ranking
4677

Overview

Charles A. Schiffer is affiliated with Wayne State University in the United States. Their research primarily focuses on the field of Medicine, with significant contributions in Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology, and Pathology and Forensic Medicine.

The scientist's work concentrates on several main topics, including:

  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • HER2/EGFR in Cancer Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment

Frequent venues for their publications include:

  • Blood
  • Haematologica
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Bone Marrow Transplantation

Charles A. Schiffer has co-authored publications most often with Jorge E. Cortés, Michael J. Mauro, Jane F. Apperley, Vivian G. Oehler, and Richard A. Larson.

Among recent papers associated with their work are:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data (2022, Blood)
  • Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial (2021, Blood)
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia (2020, JAMA Oncology)
  • Phase 2 study of ibrutinib in classic and variant hairy cell leukemia (2021, Blood)
  • Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach (2022, American Journal of Hematology)

Best Publications

  • Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

    Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith

  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

    Mayer Rj;Davis Rb;Schiffer Ca;Berg Dt

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

    Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer

  • 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*

    Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

    Kanti R. Rai;Bercedis L. Peterson;Frederick R. Appelbaum;Jonathan Kolitz

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

    B D Cheson;P A Cassileth;D R Head;C A Schiffer

  • Report of an international working group to standardize response criteria for myelodysplastic syndromes

    B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto

  • Frequency of Prolonged Remission Duration after High-Dose Cytarabine Intensification in Acute Myeloid Leukemia Varies by Cytogenetic Subtype

    Clara D. Bloomfield;David Lawrence;John C. Byrd;Andrew Carroll

  • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

    John C. Byrd;Bercedis L. Peterson;Vicki A. Morrison;Kathleen Park

  • Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Charles A. Schiffer;Kenneth C. Anderson;Charles L. Bennett;Steven Bernstein

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

    Oliver G. Ottmann;Brian J. Druker;Charles L. Sawyers;John M. Goldman

Frequent Co-Authors

Richard A. Larson
Richard A. Larson University of Chicago
Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Richard Stone
Richard Stone Harvard University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Bayard L. Powell
Bayard L. Powell Wake Forest University
Richard T. Silver
Richard T. Silver Cornell University
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Joseph O. Moore
Joseph O. Moore Duke University
Richard K. Dodge
Richard K. Dodge Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine can open doors to a variety of rewarding roles in healthcare. If you’re considering options beyond traditional medical school, there are several flexible online degrees to fit different interests and career goals.

For those interested in patient care without facing traditional entrance hurdles, there are nursing schools that don't require teas or hesi. These programs offer a practical entry point into nursing for many students.

If you prefer healthcare leadership, a healthcare administration online degree prepares you for management roles in hospitals, clinics, and public health organizations.

Nurses seeking to advance their qualifications can benefit from asn to np bridge programs, which help registered nurses earn a master’s degree and become nurse practitioners faster.

Finally, for those passionate about wellness and diet, online degrees in nutrition provide in-depth knowledge in food science and healthy living, preparing you for roles in clinical or community settings.

Best Scientists Citing Charles A. Schiffer

Trending Scientists

Recently Published Articles